Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine
暂无分享,去创建一个
K. D. Sørensen | A. Vickers | H. Lilja | M. Borre | A. Tin | J. Fredsøe | Martin Rasmussen | Jacob Fredsøe
[1] A. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. , 2021, European urology.
[2] A. Tewari,et al. Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion , 2020, International journal of urology : official journal of the Japanese Urological Association.
[3] P. Scardino,et al. A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy , 2020, British Journal of Cancer.
[4] M. Cooperberg,et al. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. , 2020, European urology.
[5] P. Choyke,et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. , 2020, The New England journal of medicine.
[6] T. H. van der Kwast,et al. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. , 2019, European urology.
[7] K. D. Sørensen,et al. Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine. , 2019, Clinical chemistry.
[8] A. Vickers,et al. Value of a Statistical Model Based on Four Kallikrein Markers in Blood, Commercially Available as 4Kscore, in All Reasonable Prostate Biopsy Subgroups. , 2018, European urology.
[9] I. Balslev,et al. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men , 2018, JAMA network open.
[10] M. Borre,et al. Multi-parametric magnetic resonance imaging monitoring patients in active surveillance for prostate cancer: a prospective cohort study , 2018, Scandinavian journal of urology.
[11] K. D. Sørensen,et al. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine. , 2017, European urology focus.
[12] H. G. van der Poel,et al. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. , 2017, European urology.
[13] F. Hamdy,et al. Properties of the 4‐Kallikrein Panel Outside the Diagnostic Gray Zone: Meta‐Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above , 2017, The Journal of urology.
[14] P. Scardino,et al. Predictive Performance evaluation Clinical Performance of the 4 Kscore Test to Predict High-grade Prostate Cancer at Biopsy : A Meta-analysis of US and European Clinical Validation Study Results , 2017 .
[15] P. Scardino,et al. Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results. , 2017, Reviews in urology.
[16] J. Fütterer,et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. , 2015, European urology.
[17] John W. Scott,et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. , 2015, European urology.
[18] P. Scardino,et al. Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study , 2015, Journal of the National Cancer Institute.
[19] D. Parekh,et al. Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. , 2015, Reviews in urology.
[20] T. Tammela,et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.
[21] B. G. Blijenberg,et al. Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.
[22] Erik Holmberg,et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.
[23] P. Scardino,et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate‐specific antigen , 2010, Cancer.
[24] V. Preedy,et al. Prospective Cohort Study , 2010 .
[25] Andrew J Vickers,et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden , 2008, BMC medicine.
[26] H. Lilja,et al. Intact Free Prostate-Specific Antigen and Free and Total Human Glandular Kallikrein 2. Elimination of Assay Interference by Enzymatic Digestion of Antibodies to F(ab')(2) Fragments. , 2006 .
[27] H. Lilja,et al. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. , 2006, Analytical chemistry.
[28] Kim Pettersson,et al. Development of sensitive immunoassays for free and total human glandular kallikrein 2. , 2004, Clinical chemistry.